scholarly journals The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes for Orthopedic Diseases Treatment

2021 ◽  
Author(s):  
Kosar Malekpour ◽  
Ali Hazrati ◽  
Marziah Zahar ◽  
Alexander Markov ◽  
Angelina Olegovna Zekiy ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Orthopedic Diseases ◽  
Potential Use

The potential use of mesenchymal stem cells for the treatment of multiple sclerosis

Life Sciences ◽  
2019 ◽  
Vol 235 ◽  
pp. 116830 ◽  
Author(s):  
Sahar Rostami Mansoor ◽  
Ebrahim Zabihi ◽  
Maryam Ghasemi-Kasman
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Potential Use

Synovial Fluid Mesenchymal Stem Cells for Knee Arthritis and Cartilage Defects: A Review of the Literature

2020 ◽  
Author(s):  
William Fang ◽  
ZhiTao Sun ◽  
Xiao Chen ◽  
Bo Han ◽  
C. Thomas Vangsness
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Synovial Fluid ◽  
Animal Studies ◽  
Adult Stem Cells ◽  
Sports Injuries ◽  
Cartilage Defects ◽  
Joint Injury ◽  
Therapeutic Properties ◽  
Potential Use

AbstractMesenchymal stem cells (MSCs) are adult stem cells that have the ability to self-renew and differentiate into several cell lineages including adipocytes, chondrocytes, tenocytes, bones, and myoblasts. These properties make the cell a promising candidate for regenerative medicine applications, especially when dealing with sports injuries in the knee. MSCs can be isolated from almost every type of adult tissue. However, most of the current research focuses on MSCs derived from bone marrow, adipose, and placenta derived products. Synovial fluid-derived MSCs (SF-MSCs) are relatively overlooked but have demonstrated promising therapeutic properties including possessing higher chondrogenic proliferation capabilities than other types of MSCs. Interestingly, SF-MSC population has shown to increase exponentially in patients with joint injury or disease, pointing to a potential use as a biomarker or as a treatment of some orthopaedic disorders. In this review, we go over the current literature on synovial fluid-derived MSCs including the characterization, the animal studies, and discuss future perspectives.

scholarly journals Potential use of mesenchymal stem cells in human meniscal repair: current insights

2017 ◽  
Vol Volume 8 ◽  
pp. 33-38 ◽  
Author(s):  
Jaewoo Pak ◽  
Jung Hun Lee ◽  
Kwang Seung Park ◽  
Jeong Ho Jeon ◽  
Sang Hee Lee
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Meniscal Repair ◽  
Potential Use

scholarly journals IMT504, the Prototype of the Immunostimulatory Oligonucleotides of the PyNTTTTGT Class, Increases the Number of Progenitors of Mesenchymal Stem Cells Both In Vitro and In Vivo: Potential Use in Tissue Repair Therapy

Stem Cells ◽  
2007 ◽  
Vol 25 (4) ◽  
pp. 1047-1054 ◽  
Author(s):  
Andrés Hernando Insúa ◽  
Alejandro D. Montaner ◽  
Juan M. Rodriguez ◽  
Fernanda Elías ◽  
Juan Fló ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Tissue Repair ◽  
Potential Use

scholarly journals Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway

2019 ◽  
Vol 10 (10) ◽  
Author(s):  
Chenyi Ye ◽  
Wei Zhang ◽  
Kai Hang ◽  
Mo Chen ◽  
Weiduo Hou ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Osteogenic Differentiation ◽  
Signaling Pathway ◽  
Akt Signaling ◽  
Specific Gene ◽  
Akt Signaling Pathway ◽  
Calvarial Bone ◽  
Marrow Mesenchymal Stem Cells ◽  
Orthopedic Diseases

Abstract Interleukin (IL)-37, a pivotal anti-inflammatory cytokine and a fundamental inhibitor of innate immunity, has recently been shown to be abnormally expressed in several autoimmune-related orthopedic diseases, including rheumatoid arthritis, ankylosing spondylitis, and osteoporosis. However, the role of IL-37 during osteogenic differentiation of mesenchymal stem cells (MSCs) remains largely unknown. In this study, extracellular IL-37 significantly increased osteoblast-specific gene expression, the number of mineral deposits, and alkaline phosphatase activity of MSCs. Moreover, a signaling pathway was activated in the presence of IL-37. The enhanced osteogenic differentiation of MSCs due to supplementation of IL-37 was partially rescued by the presence of a PI3K/AKT signaling inhibitor. Using a rat calvarial bone defect model, IL-37 significantly improved bone healing. Collectively, these findings indicate that extracellular IL-37 enhanced osteogenesis of MSCs, at least in part by activation of the PI3K/AKT signaling pathway.

scholarly journals The therapeutic potential of mesenchymal stem cells in treating osteoporosis

2021 ◽  
Vol 54 (1) ◽  
Author(s):  
Tianning Chen ◽  
Tieyi Yang ◽  
Weiwei Zhang ◽  
Jin Shao
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Therapeutic Potential ◽  
Bone Fragility ◽  
Clinical Treatment ◽  
Post Transplantation ◽  
Cell Based Therapy ◽  
Metabolic Bone ◽  
Orthopedic Diseases

AbstractOsteoporosis (OP), a common systemic metabolic bone disease, is characterized by low bone mass, increasing bone fragility and a high risk of fracture. At present, the clinical treatment of OP mainly involves anti-bone resorption drugs and anabolic agents for bone, but their long-term use can cause serious side effects. The development of stem cell therapy and regenerative medicine has provided a new approach to the clinical treatment of various diseases, even with a hope for cure. Recently, the therapeutic advantages of the therapy have been shown for a variety of orthopedic diseases. However, these stem cell-based researches are currently limited to animal models; the uncertainty regarding the post-transplantation fate of stem cells and their safety in recipients has largely restricted the development of human clinical trials. Nevertheless, the feasibility of mesenchymal stem cells to treat osteoporotic mice has drawn a growing amount of intriguing attention from clinicians to its potential of applying the stem cell-based therapy as a new therapeutic approach to OP in the future clinic. In the current review, therefore, we explored the potential use of mesenchymal stem cells in human OP treatment.

scholarly journals Nanocellulose-Based Scaffolds for Chondrogenic Differentiation and Expansion

2021 ◽  
Vol 9 ◽  
Author(s):  
Marcin Szustak ◽  
Edyta Gendaszewska-Darmach
Keyword(s):  
Mechanical Properties ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Progenitor Cells ◽  
Chondrogenic Differentiation ◽  
Recent Progress ◽  
Cartilage Tissue ◽  
Regenerative Capacity ◽  
Alternative Approach ◽  
Potential Use

Nanocellulose deserves special attention among the large group of biocompatible biomaterials. It exhibits good mechanical properties, which qualifies it for potential use as a scaffold imitating cartilage. However, the reconstruction of cartilage is a big challenge due to this tissue's limited regenerative capacity resulting from its lack of vascularization, innervations, and sparsely distributed chondrocytes. This feature restricts the infiltration of progenitor cells into damaged sites. Unfortunately, differentiated chondrocytes are challenging to obtain, and mesenchymal stem cells have become an alternative approach to promote chondrogenesis. Importantly, nanocellulose scaffolds induce the differentiation of stem cells into chondrocyte phenotypes. In this review, we present the recent progress of nanocellulose-based scaffolds promoting the development of cartilage tissue, especially within the emphasis on chondrogenic differentiation and expansion.

Sign in / Sign up

Export Citation Format

Share Document